Article
Efficacy and safety of etravirine at week 96 in treatment-experienced HIV type-1-infected patients in the DUET-1 and DUET-2 trials
Registro en:
KATLAMA, Christine. et al. Efficacy and safety of etravirine at week 96 in treatment-experienced HIV type-1-infected patients in the DUET-1 and DUET-2 trials. Antiviral Therapy, v. 15, n. 7, p. 1045-1052, 2010.
1359-6535
10.3851/IMP1662
Autor
Katlama, Christine
Clotet, Bonaventura
Mills, Anthony
Trottier, Benoit
Molina, Jean-Michel
Grinsztejn, Beatriz
Towner, William
Haubrich, Richard
Nijs, Steven
Vingerhoets, Johan
Woodfall, Brian
Witek, James
Resumen
Durable efficacy and long-term safety of antiretroviral therapy are important goals in the management of treatment-experienced patients. The 96-week efficacy and safety of the non-nucleoside reverse transcriptase inhibitor (NNRTI) etravirine were evaluated in the Phase III DUET trials. 2025-08-30